Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDLC Lowering Therapy to Later Stage Clinical Trials

Esperion Therapeutics Inc. a clinical stage biopharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein cholesterol LDLC lowering therapies for the treatment of hypercholesterolemia a...